Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma

por Zhang, Mengxian, Lahn, Michael, Huber, Peter E.
Publicado 2012

Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?

por Saleem, Azeem, Murphy, Philip, Plisson, Christophe, Lahn, Michael
Publicado 2014

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

por Maier, Armin, Peille, Anne-Lise, Vuaroqueaux, Vincent, Lahn, Michael
Publicado 2015

Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib

por van der Veen, Lars, Schmitt, Michael, Deken, Marcel A., Lahn, Michael
Publicado 2023

Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns

por Shults, Keith, Flye, Leanne, Green, Lisa, Daly, Thomas, Manro, Jason R, Lahn, Michael
Publicado 2009

Role of gammadelta T cells in protecting normal airway function

por Born, Willi K, Lahn, Michael, Takeda, Katsuyuki, Kanehiro, Arihiko, O'Brien, Rebecca L, Gelfand, Erwin W
Publicado 2000

A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation

por Maio, Michele, Lahn, Michael, Di Giacomo, Anna Maria, Covre, Alessia, Calabrò, Luana, Ibrahim, Ramy, Fox, Bernard
Publicado 2021

P1114: HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FO...

por Carlo-Stella, Carmelo, Lahn, Michael, Hammett, Tracey, van der Veen, Lars, Zorrilla, Rebeca, Pickering, Catherine, Santoro, Armando
Publicado 2023

Retrospective analysis of protein kinase C-beta (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas

por Li, Shuyu, Phong, Mark, Lahn, Michael, Brail, Leslie, Sutton, Susan, Lin, Boris K, Thornton, Donald, Liao, Birong
Publicado 2007

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

por Ikeda, Masafumi, Morimoto, Manabu, Tajimi, Masaomi, Inoue, Koichi, Benhadji, Karim A., Lahn, Michael M. F., Sakai, Daisuke
Publicado 2018

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

por O’Brien, Peter J, Ramanathan, Rajeev, Yingling, Jonathan M, Baselga, Jose, Rothenberg, Mace L, Carducci, Michael, Daly, Thomas, Adcock, Dorothy, Lahn, Michael
Publicado 2008

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

por Girvan, Allicia C, Carter, Gebra C, Li, Li, Kaltenboeck, Anna, Ivanova, Jasmina, Koh, Maria, Stevens, Jessi, Hayes-Larson, Eleanor, Lahn, Michael M
Publicado 2015

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

por Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Azaro, Analia, Seoane, Joan, Braña, Irene, Sicart, Elisabet, Miles, Colin, Lahn, Michael M, Mitchell, Malcolm I, Rodon, Jordi
Publicado 2016

Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models

por Centonze, Matteo, Di Conza, Giusy, Lahn, Michael, Fabregat, Isabel, Dituri, Francesco, Gigante, Isabella, Serino, Grazia, Scialpi, Rosanna, Carrieri, Livianna, Negro, Roberto, Pizzuto, Elena, Giannelli, Gianluigi
Publicado 2023

Correction: Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models

por Centonze, Matteo, Di Conza, Giusy, Lahn, Michael, Fabregat, Isabel, Dituri, Francesco, Gigante, Isabella, Serino, Grazia, Scialpi, Rosanna, Carrieri, Livianna, Negro, Roberto, Pizzuto, Elena, Giannelli, Gianluigi
Publicado 2023

In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography

por Pollok, Karen E., Lahn, Michael, Enas, Nathan, McNulty, Ann, Graff, Jeremy, Cai, Shanbao, Hartwell, Jennifer R., Ernstberger, Aaron, Thornton, Donald, Brail, Les, Hutchins, Gary
Publicado 2009

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

por Harding, James J., Do, Richard K., Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A., Kelley, Robin K., Abou‐Alfa, Ghassan K.
Publicado 2021

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

por COHN, ALLEN, LAHN, MICHAEL M., WILLIAMS, KRISTEN E., CLEVERLY, ANN L., PITOU, CELINE, KADAM, SUNIL K., FARMEN, MARK W., DESAIAH, DURISALA, RAJU, ROBERT, CONKLING, PAUL, RICHARDS, DONALD
Publicado 2014

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in pa...

por Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana, Cleverly, Ann Louise, Estrem, Shawn T., Wang, Shuaicheng, Lahn, Michael M., Guba, Susan C., Capper, David, Rodon, Jordi
Publicado 2020

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

por Saleem, Azeem, Matthews, Julian C., Ranson, Malcolm, Callies, Sophie, André, Valérie, Lahn, Michael, Dickinson, Claire, Prenant, Christian, Brown, Gavin, McMahon, Adam, Talbot, Denis C., Jones, Terry, Price, Patricia M.
Publicado 2011